Montelukast Sodium

This site was built with web standards. You are currently viewing the unformatted version of the website. Please update your browser in order to view the site.

Internet Explorer 5 or greater
Netscape 7
Mozilla
Opera 6 or greater

Skip navigation.

Merck

Prescribing Information

SINGULAIR®
(MONTELUKAST SODIUM)
TABLETS, CHEWABLE TABLETS, AND ORAL GRANULES

View the Prescribing Information in PDF Format [English]
View the Prescribing Information in PDF Format [Spanish]

SINGULAIR® (montelukast sodium) is a prescription medicine approved to help control asthma in adults and children as young as 12 months and to help relieve the symptoms of indoor and outdoor allergies (outdoor allergies in adults and children as young as 2 years, and indoor allergies in adults and children as young as 6 months).

IMPORTANT SAFETY INFORMATION

SINGULAIR should be taken once a day, as prescribed. SINGULAIR is available by prescription only.

Side effects are generally mild and vary by age, and may include headache, ear infection, sore throat, and upper respiratory infection. Side effects generally did not stop patients from taking SINGULAIR. SINGULAIR should not be taken by people who are sensitive to any of its ingredients.

For additional safety information, please see Patient Product Information.

This site is intended only for residents of the United States, its territories, and Puerto Rico.
SINGULAIR and MerckServices are registered trademarks of Merck & Co., Inc. MerckSource is a trademark of Merck & Co., Inc.
20851228(2)-07/08-SNG